Oral GLP-1 Pills for Weight Loss (2026): Foundayo, Wegovy Pill & All Options Compared

As of 2026, two FDA-approved oral GLP-1 pills exist for weight loss: Foundayo (orforglipron) and the Wegovy pill. Foundayo (Eli Lilly) was approved April 1, 2026 — the first non-peptide small-molecule GLP-1 agonist, achieving 12.4% mean body weight loss at 72 weeks in the ATTAIN-1 Phase 3 trial published in the New England Journal of Medicine. Oral Wegovy (Novo Nordisk's semaglutide 25mg tablet) was approved December 2025, achieving 16.6% mean body weight loss at 68 weeks in the OASIS Phase 3 trial. Both require a prescription. The core difference: Foundayo has no fasting requirement and costs from $149/month self-pay; the Wegovy pill requires a 30-minute pre-dose fast and costs $1,349/month at list price.

Quick answer — which oral GLP-1 pill is right for you:

• •No fasting, simplest routine: Foundayo from $149/mo via LillyDirect — take any time, any meal. Full Foundayo guide.
• •Highest weight loss from a pill: Wegovy pill — 16.6% vs Foundayo's 12.4%; $25/mo with commercial insurance + savings card. Wegovy pill vs injection guide.
• •Head-to-head clinical comparison: Foundayo vs Wegovy pill — trial data, efficacy, side effects, and cost side by side.
• •Want an injectable instead: Cheapest tirzepatide from $149/mo (20.9% weight loss) or all ranked GLP-1 providers.

This guide covers every FDA-approved oral GLP-1 option for weight loss, how they compare on efficacy, cost, and convenience, and who each pill is best suited for. For personalized help choosing, take the 60-second match quiz.

The 2 FDA-Approved Oral GLP-1 Pills for Weight Loss

Rybelsus is often confused with oral weight-loss GLP-1 pills — it is oral semaglutide, but at 3–14mg daily doses approved only for type 2 diabetes management. It's not FDA-approved for obesity and is not covered under weight-loss benefit pathways. The two FDA-approved oral GLP-1 options for weight loss in 2026 are Foundayo and the Wegovy pill:

Foundayo (Orforglipron): The No-Fasting Oral GLP-1

Foundayo is the first non-peptide GLP-1 pill — a small-molecule oral drug, not a biological peptide. This structural difference is why it doesn't degrade in stomach acid and requires no fasting before dosing. You can take it any time of day, with or without food or water. Foundayo was FDA-approved on April 1, 2026 for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

Cost: Foundayo's WAC (list price) is $649/month. Self-pay via LillyDirect: $149/month at the starter dose (12mg), rising to $299/month at full maintenance dosing (36–45mg). With commercial insurance + Eli Lilly's savings card: $25/month (same copay as Zepbound). Foundayo is now dispensed through Amazon Pharmacy, GoodRx, LillyDirect, and select telehealth platforms including Found, Ro, and Eden Health. Coverage is expanding as pharmacy benefit managers add Foundayo to formularies — PBM formulary activations began mid-May 2026, which historically accelerates prescription volume.

Side effects: Foundayo's most common side effects are gastrointestinal — nausea (32% vs 9% placebo), diarrhea (18%), constipation (13%), and vomiting (11%) in ATTAIN-1. Side effects were most frequent during dose escalation and decreased at steady state. No thyroid C-cell tumor warning (which appears on semaglutide and tirzepatide labeling) is present on Foundayo's label, given the different molecular mechanism.

Who is Foundayo best for? Patients who want to avoid injections, dislike strict meal-timing requirements, or are switching off compounded semaglutide injectable (the ATTAIN-MAINTAIN trial showed patients maintained nearly all their injectable GLP-1 weight loss after switching to Foundayo). The $149/month LillyDirect self-pay price makes it competitively priced against compounded injectables, with the advantage of FDA-approved status.

Oral Wegovy (Semaglutide 25mg): Higher Efficacy, Higher Price

Oral Wegovy is semaglutide — the same active ingredient as injectable Wegovy (2.4mg/week) and Ozempic — but formulated as a 25mg daily tablet using absorption technology that achieves adequate bioavailability in pill form. It was FDA-approved in December 2025, a few months before Foundayo's April 2026 approval.

The fasting requirement is the main practical challenge. Oral Wegovy must be taken with ≤4oz of plain water, on an empty stomach, at least 30 minutes before eating, drinking anything caloric, or taking other oral medications. This is because semaglutide is a peptide that degrades rapidly when food is present. Patients who forget to take it before breakfast cannot take it with food — they must wait for the next day's dose. For patients with consistent early-morning routines, this is manageable; for shift workers or those with irregular schedules, it adds friction.

Cost: $1,349/month at list price. With commercial insurance + Novo Nordisk's savings card: $25/month. Without insurance, oral Wegovy is significantly more expensive than Foundayo's $149/month LillyDirect self-pay option. One coverage advantage oral Wegovy holds: it carries an FDA cardiovascular risk reduction label — extended from the landmark SELECT trial (20% reduction in MACE in adults with obesity and established cardiovascular disease). This can unlock coverage through cardiovascular benefit pathways when standard weight-loss coverage is denied.

Side effects: Similar GI profile to Foundayo — nausea, diarrhea, constipation, vomiting, most common during dose escalation. Oral Wegovy carries the standard semaglutide boxed warning about thyroid C-cell tumors (rodent data, unknown human relevance) and contraindication in patients with personal/family history of medullary thyroid carcinoma or MEN2.

Which Oral GLP-1 Pill Should You Take?

The choice between Foundayo and the Wegovy pill comes down to three factors: fasting tolerance, insurance coverage, and weight-loss priority. Neither pill requires a history of prior GLP-1 use — both are first-line options for eligible patients.

Both pills are for the same FDA-approved indication: adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Neither is appropriate for patients under 18. For a full side-by-side breakdown including nausea rates, titration schedules, and head-to-head framing of the efficacy difference, see Foundayo vs Wegovy pill. To compare oral options against the full range of GLP-1 programs including injectables, see the GLP-1 provider rankings or take the match quiz for a personalized recommendation.

Sources